NCT02150733 - Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

July 31, 2016

Conditions

Hepatic ImpairmentSolid TumorCancer

Interventions

DRUG

Tivantinib

Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.

DRUG

Tivantinib

Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase

DRUG

Tivantinib

Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase

DRUG

Tivantinib

Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase

Trial Locations (2)

USC/Norris Comprehensive Cancer Center, Los Angeles

Hackensack